Type 2 & other diabetes

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease

Ann Intern MedPublished Target trial emulation study

Main finding · DialysisResult — go to the resultHazard ratio 0.34 95% CI 0.27–0.43

Authors' conclusion

This emulated target trial showed that SGLT2i use was associated with a lower risk for dialysis, cardiovascular events, DKA, and AKI than no SGLT2i use in patients with T2D and stage 5 CKD.

Study context

Population
Patients with T2D and stage 5 Chronic Kidney Disease (CKD), Taiwan's National Health Insurance Research Database, 1 May 2016 to 31 October 2021
Participants
23,854 vs 23,892
Comparison
SGLT2i use vs no SGLT2i use
  • SGLT2i usersn = 23,854
  • SGLT2i nonusersn = 23,892reference
Outcome
Dialysis
Methodological detailssequential target trial emulation, conditional Cox proportional hazards models
  • Sequential target trial emulation
  • Conditional Cox proportional hazards models

Main finding

As reported in the abstract

Hazard ratio

0.34

95% CI 0.27–0.43

SGLT2i usersvs SGLT2i nonusers
HR 0.34 (95% CI 0.27–0.43)

Further findings

OutcomeHR (CI)
Hospitalization for HFIntention-to-treat model0.80 (0.73–0.86)
Acute MIIntention-to-treat model0.61 (0.52–0.73)
All-cause mortalityIntention-to-treat model1.11 (0.99–1.24)

Long-term dialysis (Kaplan-Meier curves and subgroup analyses)

Initiation of an SGLT2i in stage 5 CKD associated with lower risk for long-term dialysis than no SGLT2i use

Safety

OutcomeHR (CI)
DKAIntention-to-treat model0.78 (0.71–0.85)
Acute kidney injuryIntention-to-treat model0.80 (0.70–0.90)

Original publication

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease. Ann Intern Med. Published 30 April 2024. doi:10.7326/m23-1874

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.